SMMT:NSD-Summit Therapeutics PLC (USD)

COMMON STOCK | Biotechnology |

Last Closing

USD 24.11

Change

+0.65 (+2.75)%

Market Cap

USD 27.07B

Volume

0.01B

Analyst Target

USD 4.00
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Summit Therapeutics Inc., a biopharmaceutical company, focuses on discovery, development, and commercialization of patient, physician, caregiver, and societal friendly medicinal therapies. Its lead development candidate is ivonescimab, a bispecific antibody for immunotherapy through blockade of PD-1 with the anti-angiogenesis, as well as in Phase III clinical trials for the treatment of non-small lung cancer. The company was founded in 2003 and is headquartered in Miami, Florida.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-04-28 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap
VRTX Vertex Pharmaceuticals Inc

+2.65 (+0.54%)

USD 126.52B
REGN Regeneron Pharmaceuticals Inc

+8.22 (+1.36%)

USD 69.68B
ARGX argenx NV ADR

+6.21 (+1.01%)

USD 35.43B
ALNY Alnylam Pharmaceuticals Inc

+3.29 (+1.31%)

USD 30.51B
ONC BeiGene, Ltd.

+4.56 (+1.86%)

USD 26.35B
RPRX Royalty Pharma Plc

+0.34 (+1.06%)

USD 18.40B
INSM Insmed Inc

+0.17 (+0.24%)

USD 12.52B
INCY Incyte Corporation

+0.36 (+0.61%)

USD 11.72B
BMRN Biomarin Pharmaceutical Inc

-0.32 (-0.51%)

USD 11.50B
MRNA Moderna Inc

+0.24 (+0.88%)

USD 9.91B

ETFs Containing SMMT

CNCR Loncar Cancer Immunothera.. 2.72 % 0.79 %

+0.17 (+-1.25%)

USD 7.65M
BBC Virtus LifeSci Biotech Cl.. 2.25 % 0.79 %

+0.24 (+-1.25%)

USD 0.01B
2B70:XETRA iShares Nasdaq US Biotech.. 2.09 % 0.00 %

+0.01 (+-1.25%)

USD 0.52B
BIB ProShares Ultra Nasdaq Bi.. 2.00 % 0.95 %

+1.26 (+-1.25%)

USD 0.05B
ITEK:LSE HAN-GINS Tech Megatrend E.. 1.60 % 0.00 %

-0.08 (-1.25%)

USD 0.09B
ITEP:LSE HAN-GINS Tech Megatrend E.. 1.60 % 0.00 %

-12.50 (-1.25%)

USD 0.09B
2B70:F iShares NASDAQ US Biotech.. 0.00 % 0.00 %

+0.03 (+-1.25%)

USD 0.52B

Market Performance

  Market Performance vs. Industry/Classification (Biotechnology) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 35.11% 92% A 93% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 35.11% 92% A 93% A
Trailing 12 Months  
Capital Gain 521.39% 99% N/A 99% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 521.39% 99% N/A 99% N/A
Trailing 5 Years  
Capital Gain 529.50% 98% N/A 97% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 529.50% 98% N/A 97% N/A
Average Annual (5 Year Horizon)  
Capital Gain 151.59% 87% B+ 95% A
Dividend Return 151.59% 87% B+ 95% A
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 286.67% 19% F 9% A-
Risk Adjusted Return 52.88% 95% A 80% B-
Market Capitalization 27.07B 99% N/A 97% N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

What to not like:
Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector